Gynaecological cancer
BlueStar Endo 01
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Treatment of Physician’s Choice in Participants with B7-H4-Positive Advanced/Metastatic Endometrial Cancer Who Progressed After Platinum and Anti-PD-1/Anti-PD-L1 Therapy
Trial overview
Clinical Area
Medical Oncology
Disease
Endometrial
Disease site
Gynaecology
Study Phase
Phase III
Trial Identifiers
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries